Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
•
Breast Cancer, Non-metastatic
Would you treat beyond 10 years of adjuvant hormonal therapy for premenopausal woman with high risk ER+ HER2 negative breast cancer who remain premenopausal at the end of 10 year adjuvant hormonal therapy?
What factors may influence your decision making?
Related Questions
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/HER2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?
What are your top takeaways in Medical Oncology from SABCS 2024?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?
What are your top takeaways in Breast Cancer from ESMO 2024?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?
Does delay to the time of lumpectomy impact your decision to omit radiation?
How do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies for patients with germline BRCA1/2 mutations?